CytomX Therapeutics Inc (NASDAQ: CTMX) is -41.29% lower on its value in year-to-date trading and has touched a low of $0.98 and a high of $5.85 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CTMX stock was last observed hovering at around $1.00 in the last trading session, with the day’s loss setting it -0.09%.
Currently trading at $0.91, the stock is -11.61% and -18.81% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.27 million and changing -9.00% at the moment leaves the stock -43.22% off its SMA200. CTMX registered -29.46% loss for a year compared to 6-month loss of -51.85%. The firm has a 50-day simple moving average (SMA 50) of $1.1208 and a 200-day simple moving average (SMA200) of $1.6026.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -21.55% gain in the last 1 month and extending the period to 3 months gives it a -26.02%, and is -16.51% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.00% over the week and 5.92% over the month.
CytomX Therapeutics Inc (CTMX) has around 122 employees, a market worth around $64.81M and $126.62M in sales. Current P/E ratio is 5.36. Profit margin for the company is 10.92%. Distance from 52-week low is -6.96% and -84.44% from its 52-week high.
with sales reaching $13.53M over the same period.The EPS is expected to shrink by -881.57% this year, but quarterly earnings will post 12.12% year-over-year. Quarterly sales are estimated to shrink -49.14% in year-over-year returns.
CytomX Therapeutics Inc (CTMX) Top Institutional Holders
80.0 institutions hold shares in CytomX Therapeutics Inc (CTMX), with institutional investors hold 65.86% of the company’s shares. The shares outstanding are 78.26M, and float is at 76.93M with Short Float at 7.37%. Institutions hold 65.20% of the Float.
The top institutional shareholder in the company is TANG CAPITAL MANAGEMENT LLC with over 7.79 million shares valued at $9.51 million. The investor’s holdings represent 9.4989% of the CTMX Shares outstanding. As of 2024-06-30, the second largest holder is JANUS HENDERSON GROUP PLC with 6.3 million shares valued at $7.72 million to account for 7.6826 of the shares outstanding. The other top investors are BVF INC/IL which holds 5.23 million shares representing 6.3739% and valued at over $6.38 million, while VANGUARD GROUP INC holds 5.9641 of the shares totaling 4.89 million with a market value of $5.97 million.
CytomX Therapeutics Inc (CTMX) Insider Activity
The most recent transaction is an insider sale by Landau Jeffrey B, the company’s Chief Business Officer. SEC filings show that Landau Jeffrey B sold 4,181 shares of the company’s common stock on Aug 20 ’24 at a price of $1.23 per share for a total of $5139.0. Following the sale, the insider now owns 0.12 million shares.
CytomX Therapeutics Inc disclosed in a document filed with the SEC on Aug 20 ’24 that BELVIN MARCIA (SVP, Chief Scientific Officer) sold a total of 4,181 shares of the company’s common stock. The trade occurred on Aug 20 ’24 and was made at $1.23 per share for $5139.0. Following the transaction, the insider now directly holds 0.18 million shares of the CTMX stock.
Still, SEC filings show that on Aug 20 ’24, ROWLAND LLOYD A (General Counsel) disposed off 4,181 shares at an average price of $1.23 for $5139.0. The insider now directly holds 130,797 shares of CytomX Therapeutics Inc (CTMX).
